A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy.

Background & Aims: Golexanolone is a novel small molecule GABA-A receptor-modulating steroid antagonist under development for the treatment of cognitive and vigilance disorders caused by allosteric over-activation of GABA-A receptors by neurosteroids. It restored spatial learning and motor coordination in animal models of hepatic encephalopathy (HE) and mitigated the effects of intravenous allopregnanolone in healthy adults in a dose-dependent fashion. Herein, we report data on the safety, pharmacokinetics (PK) and efficacy of golexanolone in adult patients with cirrhosis.

[Identification of chlamydia and (or) chlamydia-like microorganisms by light microscopy confirmed by electron microscopy and fluorescent in situ hybridization].

Using light microscopy, we have shown that chlamydia and/or chlamydia-like microorganisms are registered in 20-25% of the healthy part of human population, whereas in patients of the same age with gynecological problems these were found in 40-50%. Commonly, the infection was slightly manifested (less than 5% of cells are infected). These results were confirmed in four months but only in heavily infected patients.

[Experience in using hyperthermia in combination with the radon pool in the combined treatment of patients with arteriosclerosis obliterans at the Belokurikha health resort].

The patients with atherosclerosis obliterans of the peripheral arteries received sanatorium treatment at Belokurikha health resort. The treatment (thermoradonotherapy) involved hyperthermia in sauna combined with radon pool. The above combination turned out superior to conventional radonotherapy provided the procedures were well tolerated and no balneoreactions arose.